Frizzled-5

Frizzled-5 Molekülinformation

Englischer Name	Frizzled-5	Anzahl der inverkehr gebrachten Arzneimittel	0
Anzahl der klinischen Arzneimittel	1	Target-Alias	Frizzled Class Receptor 5，C2orf31，HFZ5，Frizzled 5， Seven Transmembrane Spanning Receptor，Frizzled Family Receptor 5，Fz-5，FzE5，Seven-Transmembrane Receptor Frizzled-5，Chromosome 2 Open Reading Frame 31，Frizzled (Drosophila) Homolog 5，HFz5
Höchste Forschungs- und Entwicklungsphase	Phase 1 Clinical

Englischer Name	Frizzled-5
Target-Alias	Frizzled Class Receptor 5，C2orf31，HFZ5，Frizzled 5， Seven Transmembrane Spanning Receptor，Frizzled Family Receptor 5，Fz-5，FzE5，Seven-Transmembrane Receptor Frizzled-5，Chromosome 2 Open Reading Frame 31，Frizzled (Drosophila) Homolog 5，HFz5
Anzahl der inverkehr gebrachten Arzneimittel	0
Anzahl der klinischen Arzneimittel	1
Höchste Forschungs- und Entwicklungsphase	Phase 1 Clinical

Frizzled-5 Produktliste

Attribut
Protein (1)
Produktbibliothek
Online (1)
Spezies
Human (1)
Etikett
Fc Tag (1)
Marker
Unconjugated (1)

Produktnummer	Spezies	Expressionssystem	Produktbeschreibung	Proteinstruktur	Reinheit	Eigenschaften	Vorbestellen/Bestellen
FZ5-H5259	Human	HEK293	Human Frizzled-5 / FZD5 Protein, Fc Tag (MALS verified)				In den Warenkorb legen

Gesamtmenge1

Frizzled-5 Molekülhintergrund

Frizzled-5 (FZD5) is also known as FzE5, which belongs to the G-protein coupled receptor Fz/Smo family. Most of frizzled receptors are coupled to the beta-catenin canonical signaling pathway, which leads to the activation of disheveled proteins, inhibition of GSK-3 kinase, nuclear accumulation of beta-catenin and activation of Wnt target genes. FZD5 contains one FZ (frizzled) domain. FZD5 may be involved in transduction and intercellular transmission of polarity information during tissue morphogenesis and/or in differentiated tissues. FZD5 interacts specifically with Wnt5A to induce the beta-catenin pathway. FZD5 interacts with GOPC.

Frizzled-5 Molekülalias

FZD5,Frizzled-5,C2orf31,,Fz-5,hFz5,FzE5

Klinische Arzneimittelinformation

Englischer Name	Forschungscode	Forschungsphase	Firma	Indikationen	Klinische Studie
Vantictumab	OMP-18R5; anti-Fzd7	Phase 1 Clinical	Bayer AG, Oncomed Pharmaceuticals Inc	Carcinoma, Non-Small-Cell Lung; Metastatic breast cancer; Osteopetrosis; Pancreatic Neoplasms; Solid tumours	Details